1. Scrip
  2. >>Business
  3. >>Earnings

Amgen Optimistic About Growth, Despite Denosumab Biosimilars, Potential Tariffs

MariTide Phase II Obesity Details Planned For ADA

 
• By Mandy Jackson

Amgen saw revenue rise 19% to $33.4bn in 2024 and said revenue should grow to $34.3bn-$35.7bn in 2025 despite losing exclusivity for its biggest franchise – Prolia and Xgeva (denosumab) – this year.

Repatha, Evenity and eight other Amgen products had double- or triple-digit growth in 2024 (Shutterstock)

While regulatory uncertainty in the US is mounting, Amgen does not expect significant revenue impact from new tariffs implemented under US President Donald Trump, chief financial officer Peter Griffith told Scrip. The newly implemented tariffs have prompted questions for big pharmas already coping with the changing US regulatory regime, but Amgen has limited exposure. The company reported strong performance in 2024 on 4 February, with fourth-quarter and full-year 2024 revenues that exceeded analyst consensus and guidance for 2025 that anticipates revenue growth, despite loss of exclusivity for the company’s largest franchise, denosumab.

With 10 products across Amgen’s portfolio generating double-digit or greater sales growth and 14 products annualizing at $1bn or more...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

PTC Projects Confidence In Sephience Launch With Royalty Buyback

 
• By Manas Mishra

The company will start shipping its newly launched phenylketonuria drug within two weeks and has bought back global net sales obligations for the treatment.

Lilly Confident In Orforglipron Despite Disappointing Phase III Data

 
• By Mandy Jackson

Lilly spent much of its earnings call defending orforglipron as analysts lamented its results in obesity versus Novo’s semaglutide, overshadowing strong Q2 revenue growth driven by existing GLP-1/GIP franchise Mounjaro/Zepbound.

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.

Korea Q2 Roundup: Global Sales, License Income Boost Yuhan, GC

 
• By Jung Won Shin

Yuhan and GC Biopharma’s performances stood out among South Korean companies reporting Q2 results, boosted by license income, strong global growth and exports, while many others reported generally weaker figures.

More from Scrip